Related content

Time Factor in Radiotherapy and Chemotherapy for Limited Disease Small-Cell Lung Cancer

By Nowara Elzbieta   Suwinski Rafal  

Cancer Investigation, Vol. 25, Iss. 3, 2007-04 ,pp. : 163-171

Informa Healthcare

Access to resources Recommend Favorite

Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer

By Oka M.   Fukuda M.   Kuba M.   Ichiki M.   Rikimaru T.   Soda H.   Tsurutani J.   Nakamura Y.   Kawabata S.   Nakatomi K.   Narasaki F.   Nagashima S.   Takatani H.   Fukuda M.   Kinoshita A.   Kohno S.  

European Journal of Cancer, Vol. 38, Iss. 15, 2002-10 ,pp. : 1998-2004

Elsevier

Access to resources Recommend Favorite

Chemoradiotherapy for Limited-disease Small-cell Lung Cancer in Elderly Patients Aged 75 Years or Older

By Shukuya Takehito   Takahashi Toshiaki   Harada Hideyuki   Ono Akira   Akamatsu Hiroaki   Taira Tetsuhiko   Kenmotsu Hirotsugu   Naito Tateaki   Murakami Haruyasu   Endo Masahiro   Takahashi Kazuhisa   Yamamoto Nobuyuki  

Japanese Journal of Clinical Oncology, Vol. 43, Iss. 2, 2013-02 ,pp. : 176-183

Oxford University Press

Access to resources Recommend Favorite

Accelerated hyperfractionated radiotherapy and concomitant chemotherapy in small cell lung cancer limited-disease. Dose response, feasibility and outcome for patients treated in western Sweden, 1998-2004.

By Hallqvist Andreas   Rylander Hillevi   Björk-Eriksson Thomas   Nyman Jan  

Acta Oncologica, Vol. 46, Iss. 7, 2007-01 ,pp. : 969-974

Informa Healthcare

Access to resources Recommend Favorite

Definitive chemoradiotherapy of limited-disease small cell lung cancer: Retrospective analysis of new predictive factors affecting treatment results

By            

Oncology Letters, Vol. 2, Iss. 5, 2011-01 ,pp. : 855-860

Spandidos Publications

Access to resources Recommend Favorite